XML 59 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Notes Payable (Details Narrative)
3 Months Ended 6 Months Ended
Aug. 09, 2017
USD ($)
Nov. 12, 2015
USD ($)
$ / shares
shares
Jun. 26, 2015
USD ($)
Jan. 22, 2015
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Amount of loan obligation         $ 8,462,889   $ 8,462,889   $ 9,951,512
Recognized amortization of deferred financing costs         37,739 $ 44,531 78,735 $ 88,572  
Unamortized debt issuance costs         314,492   314,492   393,227
Interest expense paid         305,687 $ 187,077 $ 575,863 $ 434,441  
Year-End Adjustment [Member]                  
Payroll reduction of interest rate             0.13    
Net sales             $ 15,000,000    
June 26, 2015 Security Agreement [Member] | U.S [Member]                  
Percentage of sale revenue net     5.00%            
June 26, 2015 Security Agreement [Member] | June 30, 2016 [Member]                  
Note payable     $ 250,000            
June 26, 2015 Security Agreement [Member] | June 30, 2016 [Member] | Minimum [Member]                  
Note payable     12,500            
June 26, 2015 Security Agreement [Member] | Quarter Ending September 30, 2015 [Member]                  
Note payable     $ 700,000            
Neuragen Corp [Member] | June 26, 2015 Security Agreement [Member]                  
Debt instrument interest rate percentage     0.00%            
Note principal amount     $ 950,000            
Total payments of acquire assets     $ 1,200,000            
Neuragen Corp [Member] | June 26, 2015 Security Agreement [Member] | U.S [Member]                  
Percentage of sale revenue net     2.00%            
Loan Agreement [Member] | Knight Therapeutics Inc [Member]                  
Loan amount $ 10,000,000 $ 5,500,000   $ 6,000,000          
Expenses associated with loan $ 100,000 $ 24,000   $ 40,000          
Debt instrument interest rate percentage 10.50% 15.00%   15.00%          
Convertible equity offering       $ 1,000,000          
Change in loan interest rate   13.00%   13.00%          
Note maturity date Aug. 08, 2020 Nov. 11, 2017   Jan. 20, 2017          
Revenue       $ 13,000,000          
Net income (loss)       2,000,000          
Recognized and paid interest expense       4,611          
Accrued interest expense       $ 0          
Common stock purchase price per share | $ / shares   $ 0.49              
Percentage of shares purchasable under warrants   6.50%              
Deferred financing costs         289,045   289,045    
Recognized amortization of deferred financing costs             3,257    
Unamortized debt issuance costs         0   0    
Warrants term   10 years              
Credit facility maximum borrowing amount $ 20,000,000                
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | Second Amendment [Member]                  
Accrued interest expense         0   0    
Deferred financing costs         452,869   452,869    
Recognized amortization of deferred financing costs         37,739   78,735    
Unamortized debt issuance costs         314,492   314,492    
Note payable         8,500,000   8,500,000    
Interest expense paid         286,361   528,444    
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | ST Warrant [Member]                  
Number of warrants to purchase common stock | shares       4,595,187          
Warrants exercise price | $ / shares       $ 1.00          
Beneficial conversion feature of warrants       $ 1,952,953          
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | LT Warrant [Member]                  
Number of warrants to purchase common stock | shares       3,584,759          
Warrants exercise price | $ / shares       $ 0.34          
Common stock purchase price per share | $ / shares       $ 1.00          
Percentage of shares purchasable under warrants       25.00%          
Beneficial conversion feature of warrants       $ 1,462,560          
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | Knight Warrant Shares [Member]                  
Number of warrants to purchase common stock | shares   5,550,625              
Amortization of debt discount   $ 2,553,287              
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | Knight Warrant Shares [Member] | Maximum [Member]                  
Number of warrants to purchase common stock | shares   4,547,243              
Amortization of debt discount   $ 2,067,258              
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | January 22, 2015 Loan One [Member]                  
Debt instrument interest rate percentage       5.00%          
Amount of loan obligation       $ 300,000          
Aggregate consideration to be paid       100,000          
Capital expenditures       100,000          
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | Origination Fee [Member]                  
Expenses associated with loan 200,000 110,000   120,000          
Loan Agreement [Member] | Knight Therapeutics Inc [Member] | Work Fee [Member]                  
Expenses associated with loan 100,000 $ 55,000   60,000          
Recognized and paid interest expense       $ 0          
Security Agreement [Member]                  
Payments of debt issuance costs         12,500   25,000    
Security Agreement [Member] | June 26, 2015 Security Agreement [Member]                  
Deferred financing costs         10,486   10,486    
Recognized amortization of deferred financing costs             0    
Unamortized debt issuance costs         0   0    
Present value of future payments         277,381   277,381   $ 282,240
Interest expense paid         $ 10,026   $ 20,141    
Covenants [Member]                  
Loan amount $ 5,000,000                
Debt instrument interest rate percentage 5.00%